ACUCELA INC in Seattle, Washington
Web Results:
- Acucela
THE DISEASE THE SCIENCE THE PROGRESS The Disease Dry age-related macular degeneration (dry AMD) is the most common form of AMD -- in its early or intermediate stages. There are currently no medications approved to treat geographic atrophy (GA), the most advanced form of dry AMD. There are more than ...- Acucela
THE DISEASE THE SCIENCE THE PROGRESS The Science The Visual Cycle Cells within the back of the eye convert dietary vitamin A to a light-sensitive compound in a process referred to as the visual cycle. During exposure to bright light, the visual cycle is extremely active and can produce toxic vitamin...- Acucela
THE DISEASE THE SCIENCE THE PROGRESS The Progress Acucela's candidate drug, emixustat hydrochloride is a VCM product candidate currently in clinical development for the treatment of geographic atrophy associated with dry AMD, known as (GA). The oral availability of emixustat hydrochloride and its ab...
Business Information:
| In Business Since: | 2002 |
| Business Sector: | Residential, Commercial |
